Jade Biosciences, Inc. (JBIO)
NASDAQ:JBIO
Want to see JBIO full AI Analyst Report?
JBIO Stock Chart & Stats
$22.85
--
Market closed
$22.85
--
Day’s Range― - ―
52-Week Range$6.57 - $28.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)842.35K
Market Cap
$903.46M
Enterprise Value$632.04M
Total Cash (Recent Filing)$311.30M
Total Debt (Recent Filing)$679.00K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 17, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend Yield14.68%
Share Statistics
EPS (TTM)-2.92
Shares Outstanding59,359,875
10 Day Avg. Volume1,445,490
30 Day Avg. Volume842,354
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-70.23K
Enterprise Value/Ebitda-4.73
Forecast
1Y Price Target
$49.00Price Target Upside114.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 1 DataRobust Phase 1 safety and PD (rapid, durable APRIL suppression and ~70% IgA reduction) materially de-risks the program biologically. Durable target engagement and extended half-life support potential differentiated dosing and competitive positioning if efficacy is confirmed in later trials.
Accelerated Development PathMoving quickly from Phase 1 to an active Phase 2 and planning a registrational Phase 3 provides a clear development timeline and near-term milestones. Accelerated program cadence increases potential for value inflection events and clearer de-risking over the 2–6 month horizon.
Substantial Equity FinancingA large underwritten equity raise meaningfully extends cash runway to fund clinical trials, manufacturing and R&D. Improved liquidity reduces immediate financing pressure and supports uninterrupted development of lead programs through key upcoming clinical readouts.
Bears Say
Pre-revenue, Widening LossesThe company remains pre-revenue with materially widening net losses, meaning all value depends on future trial success or partnerships. Continued losses erode equity and create execution risk: until commercialization or licensing, shareholder returns hinge on successful late-stage trials.
High Cash Burn And Negative Cash FlowSustained negative operating and free cash flow require recurrent capital raises or strategic partnerships. Even with recent FCF improvement, the large burn rate increases financing dependence and could force dilutive raises if development costs continue at current levels without revenue.
Equity Erosion And Dilution RiskDeclining equity and deeply negative ROE reflect ongoing value erosion from operating losses. Large external financings (current offering) mitigate runway but increase dilution risk, pressuring long-term per-share value unless clinical success translates into revenue or high-value partnerships.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences, Inc.’s price range in the past 12 months?
Jade Biosciences, Inc. lowest stock price was $6.57 and its highest was $28.00 in the past 12 months.
What is Jade Biosciences, Inc.’s market cap?
Jade Biosciences, Inc.’s market cap is $903.46M.
When is Jade Biosciences, Inc.’s upcoming earnings report date?
Jade Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 67 days.
How were Jade Biosciences, Inc.’s earnings last quarter?
Jade Biosciences, Inc. released its earnings results on May 08, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.483 by -$0.087.
Is Jade Biosciences, Inc. overvalued?
According to Wall Street analysts Jade Biosciences, Inc.’s price is currently Undervalued.
Does Jade Biosciences, Inc. pay dividends?
Jade Biosciences, Inc. pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 14.68%. See more information on Jade Biosciences, Inc. dividends here
What is Jade Biosciences, Inc.’s EPS estimate?
Jade Biosciences, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Jade Biosciences, Inc. have?
Jade Biosciences, Inc. has 59,359,875 shares outstanding.
What happened to Jade Biosciences, Inc.’s price movement after its last earnings report?
Jade Biosciences, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.483. Following the earnings report the stock price went up 6.565%.
Which hedge fund is a major shareholder of Jade Biosciences, Inc.?
Currently, no hedge funds are holding shares in JBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jade Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (114.44% Upside)
$49.00 (114.44% Upside)
Blogger Sentiment
Bearish
JBIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 333.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.8%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Bullish
Bullish news 79%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.40%
12-Months-Change
Fundamentals
Return on Equity
-51.34%
Trailing 12-Months
Asset Growth
312.00%
Trailing 12-Months
Company Description
Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO Stock 12 Month Forecast
Average Price Target
$49.00
▲(114.44% Upside)
Technical Analysis
Ownership Overview
10.32% Insiders
17.04% Mutual Funds
58.06% Other Institutional Investors
7.32% Public Companies and Individual Investors